An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes

Human Molecular Genetics

Volumn 25, Issue 17, 2016, Pages 3654-3675

  Southwell, Amber L ^a   Smith Dijak, Amy ^b   Kay, Chris ^a   Sepers, Marja ^b   Villanueva, Erika B ^a   Parsons, Matthew P ^b   Xie, Yuanyun ^a   Anderson, Lisa ^a   Felczak, Boguslaw ^a   Waltl, Sabine ^a   Ko, Seunghyun ^a   Cheung, Daphne ^a   Cengio, Louisa Dal ^a   Slama, Ramy ^a   Petoukhov, Eugenia ^a   Raymond, Lynn A ^b   Hayden, Michael R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID RECEPTOR; CRE RECOMBINASE; DOPAMINE 2 RECEPTOR; HUNTINGTIN; NEOMYCIN; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; PHOSPHOPROTEIN DARPP 32; UNCLASSIFIED DRUG; VESICULAR GLUTAMATE TRANSPORTER 1; HTT PROTEIN, MOUSE;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BEHAVIOR CHANGE; BODY WEIGHT; BRAIN HISTOLOGY; BRAIN WEIGHT; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; EXCITATORY POSTSYNAPTIC POTENTIAL; FEMALE; FOREBRAIN; GENE EXPRESSION; GENE LOCUS; HETEROZYGOSITY; HOMOZYGOSITY; HUNTINGTON CHOREA; IMMUNOREACTIVITY; LOCOMOTION; LOXP SITE; MALE; MOUSE; NERVE CELL EXCITABILITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; START CODON; TESTIS ATROPHY; TONIC CLONIC SEIZURE; TRANSCRIPTION INITIATION SITE; VOLUMETRY; ANIMAL; ANIMAL BEHAVIOR; CROSS BREEDING; DISEASE MODEL; GENE TARGETING; GENETICS; HETEROZYGOTE; HUMAN; MUTATION; PATHOLOGY; PROCEDURES;

ANIMALS; BEHAVIOR, ANIMAL; CROSSES, GENETIC; DISEASE MODELS, ANIMAL; GENE KNOCK-IN TECHNIQUES; HETEROZYGOTE; HUMANS; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; MICE; MUTATION; PHENOTYPE;

EID: 85014377300     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddw212     Document Type: Article

References (72)

1. Evans, S.J.W., Douglas, I., Rawlins, M.D., Wexler, N.S., Tabrizi, S.J. and Smeeth, L. (2013) Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records. J. Neurol. Neurosurg. Psychiatry., 84, 1156-1160.
2. Fisher, E.R. and Hayden, M.R. (2014) Multisource ascertainment of Huntington disease in Canada: Prevalence and population at risk. Mov. Disord., 29, 105-114.
3. Ross, C.A. and Tabrizi, S.J. (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. The Lancet Neurol., 10, 83-98.
4. Shannon, K.M. and Fraint, A. (2015) Therapeutic advances in Huntington's Disease. Mov. Disord., 30, 1539-1546.
5. The Huntington's Disease Collaborative Research Group(1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72, 971-983.
6. Andrew, S.E., Goldberg, Y.P., Kremer, B., Telenius, H., Theilmann, J., Adam, S., Starr, E., Squitieri, F., Lin, B., Kalchman, M.A., et al. (1993) The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat. Genet., 4, 398-403.
7. White, J.K., Auerbach, W., Duyao, M.P., Vonsattel, J.P., Gusella, J.F., Joyner, A.L. and MacDonald, M.E. (1997) Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat. Genet., 17, 404-410.
8. Menalled, L.B., Sison, J.D., Dragatsis, I., Zeitlin, S. and Chesselet, M.F. (2003) Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J. Comp. Neurol., 465, 11-26.
9. Shelbourne, P.F., Killeen, N., Hevner, R.F., Johnston, H.M., Tecott, L., Lewandoski, M., Ennis, M., Ramirez, L., Li, Z., Iannicola, C., et al. (1999) A Huntington's Disease CAG Expansion at the Murine Hdh Locus Is Unstable and Associated with Behavioural Abnormalities in Mice. Hum. Mol. Genet., 8, 763-774.
10. Lin, C.H., Tallaksen-Greene, S., Chien, W.M., Cearley, J.A., Jackson, W.S., Crouse, A.B., Ren, S., Li, X.J., Albin, R.L. and Detloff, P.J. (2001) Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Genet., 10, 137-144.
11. Wheeler, V.C., Auerbach, W., White, J.K., Srinidhi, J., Auerbach, A., Ryan, A., Duyao, M.P., Vrbanac, V., Weaver, M., Gusella, J.F., et al. (1999) Length-Dependent Gametic CAG Repeat Instability in the Huntington's Disease Knock-in Mouse. Hum. Mol. Genet., 8, 115-122.
12. Levine, M.S., Klapstein, G.J., Koppel, A., Gruen, E., Cepeda, C., Vargas, M.E., Jokel, E.S., Carpenter, E.M., Zanjani, H., Hurst, R.S., et al. (1999) Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res., 58, 515-532.
13. Reddy, P.H., Williams, M., Charles, V., Garrett, L., Pike-Buchanan, L., Whetsell, W.O., Miller, G. and Tagle, D.A. (1998) Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat. Genet., 20, 198-202.
14. Gray, M., Shirasaki, D.I., Cepeda, C., André, V.M., Wilburn, B., Lu, X.H., Tao, J., Yamazaki, I., Li, S.H., Sun, Y.E., et al. (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci., 28, 6182-6195.
15. Slow, E.J., van Raamsdonk, J., Rogers, D., Coleman, S.H., Graham, R.K., Deng, Y., Oh, R., Bissada, N., Hossain, S.M., Yang, Y.Z., et al. (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet., 12, 1555-1567.
16. Hodgson, J.G., Agopyan, N., Gutekunst, C.A., Leavitt, B.R., LePiane, F., Singaraja, R., Smith, D.J., Bissada, N., McCutcheon, K., Nasir, J., et al. (1999) A YAC Mouse Model for Huntington's Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration. Neuron, 23, 181-192.
17. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S.W., et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat Is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87, 493-506.
18. Schilling, G., Becher, M.W., Sharp, A.H., Jinnah, H.A., Duan, K., Kotzuk, J.A., Slunt, H.H., Ratovitski, T., Cooper, J.K., Jenkins, N.A., et al. (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet., 8, 397-407.
19. Brooks, S.P. and Dunnett, S.B. (2015) Mouse Models of Huntington's Disease. In Nguyen, P.H.H.nd Cenci, A.M. (eds.), Behavioral Neurobiology of Huntington's Disease and Parkinson's Disease. Springer Berlin Heidelberg, Berlin, Heidelberg, pp. 101-133.
20. Pouladi, M.A., Morton, A.J. and Hayden, M.R. (2013) Choosing an animal model for the study of Huntington's disease. Nat. Rev. Neurosci., 14, 708-721.
21. Menalled, L.B., Kudwa, A.E., Miller, S., Fitzpatrick, J., Watson-Johnson, J., Keating, N., Ruiz, M., Mushlin, R., Alosio, W., McConnell, K., et al. (2012) Comprehensive Behavioral and Molecular Characterization of a New Knock-In Mouse Model of Huntington's Disease: zQ175. PLoS ONE, 7, e49838.
22. Heikkinen, T., Lehtimaki, K., Vartiainen, N., Puolivali, J., Hendricks, S.J., Glaser, J.R., Bradaia, A., Wadel, K., Touller, C., Kontkanen, O., et al. (2012) Characterization of Neurophysiological and Behavioral Changes, MRI Brain Volumetry and 1H MRS in zQ175 Knock-In Mouse Model of Huntington's Disease. PLoS ONE, 7, e50717.
23. Van Raamsdonk, J.M., Metzler, M., Slow, E., Pearson, J., Schwab, C., Carroll, J., Graham, R.K., Leavitt, B.R. and Hayden, M.R. (2007) Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiol. Dis., 26, 189-200.
24. Mantovani, S., Gordon, R., Li, R., Christie, D.C., Kumar, V. and Woodruff, T.M. (2016) Motor deficits associated with Huntington's disease occur in the absence of striatal degeneration in BACHD transgenic mice. Hum. Mol. Genet., pii: ddw050. [Epub ahead of print].
25. Pouladi, M.A., Stanek, L.M., Xie, Y., Franciosi, S., Southwell, A.L., Deng, Y., Butland, S., Zhang, W., Cheng, S.H., Shihabuddin, L.S., et al. (2012) Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Hum. Mol. Genet., 21, 2219-2232.
26. Southwell, A.L., Ko, J. and Patterson, P.H. (2009) Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J. Neurosci., 29, 13589-13602.
27. Gogliotti, R.G., Lutz, C., Jorgensen, M., Huebsch, K., Koh, S. and DiDonato, C.J. (2011) Characterization of a commonly used mouse model of SMA reveals increased seizure susceptibility and heightened fear response in FVB/N mice. Neurobiol. Dis., 43, 142-151.
28. Pham, C.T.N., MacIvor, D.M., Hug, B.A., Heusel, J.W. and Ley, T.J. (1996) Long-range disruption of gene expression by a selectable marker cassette. Proc. Natl. Acad. Sci. U S A, 93, 13090-13095.
29. Holzenberger, M., Lenzner, C., Leneuve, P., Zaoui, R., Hamard, G., Vaulont, S. and Bouc, Y.L. (2000) Cre-mediated germline mosaicism: a method allowing rapid generation of several alleles of a target gene. Nucleic Acids Res., 28, e92.
30. Gallardo, T., Shirley, L., John, G.B. and Castrillon, D.H. (2007) Generation of a germ cell-specific mouse transgenic Cre line, Vasa-Cre. Genesis, 45, 413-417.
31. Graham, R.K., Slow, E.J., Deng, Y., Bissada, N., Lu, G., Pearson, J., Shehadeh, J., Leavitt, B.R., Raymond, L.A. and Hayden, M.R. (2006) Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. Neurobiol. Dis., 21, 444-455.
32. Strong, M.K., Southwell, A.L., Yonan, J.M., Hayden, M.R., MacGregor, G.R., Thompson, L.M. and Steward, O. (2012) Age-Dependent Resistance to Excitotoxicity in Htt CAG140 Mice and the Effect of Strain Background. J. Huntingtons Dis., 1, 221-241.
33. Ghosh, R. and Tabrizi, S. (2013) Clinical Aspects of Huntington's Disease. In Current Topics in Behavioral Neuroscience. Springer Berlin Heidelberg, pp. 1-29.
34. Heng, M.Y., Detloff, P.J. and Albin, R.L. (2008) Rodent genetic models of Huntington disease. Neurobiol. Dis., 32, 1-9.
35. Southwell, A.L., Warby, S.C., Carroll, J.B., Doty, C.N., Skotte, N.H., Zhang, W., Villanueva, E.B., Kovalik, V., Xie, Y., Pouladi, M.A., et al. (2013) A fully humanized transgenic mouse model of Huntington disease. Hum. Mol. Genet., 22, 18-34.
36. Van Raamsdonk, J.M., Murphy, Z., Selva, D.M., Hamidizadeh, R., Pearson, J., Petersen, A., Bjorkqvist, M., Muir, C., Mackenzie, I.R., Hammond, G.L., et al. (2007) Testicular degeneration in Huntington disease. Neurobiol. Dis., 26, 512-520.
37. Papalexi, E., Persson, A., Björkqvist, M., Petersén, A., Woodman, B., Bates, G.P., Sundler, F., Mulder, H., Brundin, P. and Popovic, N. (2005) Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease. Eur. J. Neurosci., 22, 1541-1546.
38. Leavitt, B.R., Guttman, J.A., Hodgson, J.G., Kimel, G.H., Singaraja, R., Vogl, A.W. and Hayden, M.R. (2001) Wild-Type Huntingtin Reduces the Cellular Toxicity of Mutant Huntingtin In Vivo. Am. J. Hum. Genet., 68, 313.
39. The Huntington Study Group (1996) Unified Huntington's disease rating scale: Reliability and consistency. Mov. Disord., 11, 136-142.
40. Pouladi, M.A., Graham, R.K., Karasinska, J.M., Xie, Y., Santos, R.D., Petersen, A. and Hayden, M.R. (2009) Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain, 132, 919-932.
41. Novak, M.J.U. and Tabrizi, S.J. (2010) Huntington's disease. BMJ, 340, c3109.
42. Van Raamsdonk, J.M., Pearson, J., Slow, E.J., Hossain, S.M., Leavitt, B.R. and Hayden, M.R. (2005) Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. J. Neurosci., 25, 4169-4180.
43. Vonsattel, J. (2008) Huntington disease models and human neuropathology: similarities and differences. Acta Neuropathol., 115, 55-69.
44. Tabrizi, S.J., Scahill, R.I., Owen, G., Durr, A., Leavitt, B.R., Roos, R.A., Borowsky, B., Landwehrmeyer, B., Frost, C., Johnson, H., et al. (2013) Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol., 12, 637-649.
45. Gutekunst, C.A., Li, S.H., Yi, H., Mulroy, J.S., Kuemmerle, S., Jones, R., Rye, D., Ferrante, R.J., Hersch, S.M. and Li, X.J. (1999) Nuclear and Neuropil Aggregates in Huntington's Disease: Relationship to Neuropathology. J.Neurosci., 19, 2522-2534.
46. Wang, C.E., Zhou, H., McGuire, J.R., Cerullo, V., Lee, B., Li, S.H. and Li, X.J. (2008) Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J. Cell Biol., 181, 803-816.
47. Hodges, A., Strand, A.D., Aragaki, A.K., Kuhn, A., Sengstag, T., Hughes, G., Elliston, L.A., Hartog, C., Goldstein, D.R., Thu, D., et al. (2006) Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Genet., 15, 965-977.
48. Nisenbaum, E.S. and Wilson, C.J. (1995) Potassium currents responsible for inward and outward rectification in rat neostriatal spiny projection neurons. J. Neurosci., 15, 4449-4463.
49. Klapstein, G.J., Fisher, R.S., Zanjani, H., Cepeda, C., Jokel, E.S., Chesselet, M.F. and Levine, M.S. (2001) Electrophysiological and Morphological Changes in Striatal Spiny Neurons in R6/2 Huntington's Disease Transgenic Mice. J. Neurophysiol., 86, 2667-2677.
50. Chiu, C.S., Brickley, S., Jensen, K., Southwell, A., McKinney, S., Cull-Candy, S., Mody, I. and Lester, H.A. (2005) GABA Transporter Deficiency Causes Tremor, Ataxia, Nervousness, and Increased GABA-Induced Tonic Conductance in Cerebellum. J. Neurosci., 25, 3234-3245.
51. Auerbach, W., Hurlbert, M.S., Hilditch-Maguire, P., Wadghiri, Y.Z., Wheeler, V.C., Cohen, S.I., Joyner, A.L., MacDonald, M.E. and Turnbull, D.H. (2001) The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin. Hum. Mol. Genet., 10, 2515-2523.
52. Harigaya, Y. and Parker, R. (2010) No-go decay: a quality control mechanism for RNA in translation. Wiley Interdisciplinary Reviews-RNA, 1, 132-141.
53. Mattis, V.B., Tom, C., Akimov, S., Saeedian, J., Oestergaard, M.E., Southwell, A.L., Doty, C.N., Ornelas, L., Sahabian, A., Lenaeus, L., et al. (2015) HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity. Hum. Mol. Genet., 24, 3257-3271.
54. The HD iPsc Consortium(2012) Induced Pluripotent Stem Cells from Patients with Huntington's Disease Show CAGRepeat-Expansion-Associated Phenotypes. Cell Stem Cell, 11, 264-278.
55. Aronin, N., Chase, K., Young, C., Sapp, E., Schwarz, C., Matta, N., Kornreich, R., Lanwehrmeyer, B., Bird, E., Beal, M.F., et al. (1995) CAG expansion affects the expression of mutant huntingtin in the Huntington's disease brain. Neuron, 15, 1193-1201.
56. Evers, M.M., Schut, M.H., Pepers, B.A., Atalar, M., van Belzen, M.J., Faull, R.L.M., Roos, R.A.C. and van Roon-Mom, W.M.C. (2015) Making (anti-) sense out of huntingtin levels in Huntington disease. Mol. Neurodegener., 10, 1-11.
57. Liu, W., Chaurette, J., Pfister, E.L., Kennington, L.A., Chase, K.O., Bullock, J., Vonsattel, J.P.G., Faull, R.L.M., Macdonald, D., DiFiglia, M., et al. (2014) Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain. J. Huntington's Dis., 2, 491-500.
58. Schauwecker, P.E. and Steward, O. (1997) Genetic determinants of susceptibility to excitotoxic cell death: Implications for gene targeting approaches. Proc. Natl Acad. Sci. USA, 94, 4103-4108.
59. Zuccato, C., Valenza, M. and Cattaneo, E. (2010) Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease. Physiol. Rev., 90, 905-981.
60. Markianos, M., Panas, M., Kalfakis, N. and Vassilopoulos, D. (2005) Plasma testosterone in male patients with Huntington's disease: Relations to severity of illness and dementia. Ann. Neurol., 57, 520-525.
61. Vonsattel, J.P. and DiFiglia, M. (1998) Huntington Disease. J. Neuropathol. Exp. Neurol., 57, 369-384.
62. Carroll, J.B., Lerch, J.P., Franciosi, S., Spreeuw, A., Bissada, N., Henkelman, R.M. and Hayden, M.R. (2011) Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease. Neurobiol. Dis., 43, 257-265.
63. Hedreen, J.C., Peyser, C.E., Folstein, S.E. and Ross, C.A. (1991) Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci. Lett., 133, 257-261.
64. Kuhn, A., Goldstein, D.R., Hodges, A., Strand, A.D., Sengstag, T., Kooperberg, C., Becanovic, K., Pouladi, M.A., Sathasivam, K., Cha, J.H.J., et al. (2007) Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum. Mol. Genet., 16, 1845-1861.
65. Squitieri, F., Gellera, C., Cannella, M., Mariotti, C., Cislaghi, G., Rubinsztein, D.C., Almqvist, E.W., Turner, D., Bachoud-Levi, A.C., Simpson, S.A., et al. (2003) Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain, 126, 946-955.
66. Taketo, M., Schroeder, A., Mobraaten, L., Gunning, K., Hanten, G., Fox, R., Roderick, T., Stewart, C., Lilly, F. and Hansen, C. (1991) FVB/N: an inbred mouse strain preferable for transgenic analyses. Proc. Natl. Acad. Sci. U S A, 88, 2065.
67. Romberg, C., Horner, A.E., Bussey, T.J. and Saksida, L.M. (2013) A touch screen-automated cognitive test battery reveals impaired attention, memory abnormalities, and increased response inhibition in the TgCRND8 mouse model of Alzheimer's disease. Neurobiol. Aging, 34, 731-744.
68. Trueman, R.C., Brooks, S.P., Jones, L. and Dunnett, S.B. (2007) The operant serial implicit learning task reveals early onset motor learning deficits in the Hdh knock-in mouse model of Huntington's disease. Eur. J. Neurosci., 25, 551-558.
69. Pinto, R.M., Dragileva, E., Kirby, A., Lloret, A., Lopez, E., St. Claire, J., Panigrahi, G.B., Hou, C., Holloway, K., Gillis, T., et al. (2013) Mismatch Repair Genes Mlh1 and Mlh3 Modify CAG Instability in Huntington's Disease Mice: Genome-Wide and Candidate Approaches. PLoS Genet., 9, e1003930.
70. Carroll, J., Southwell, A., Graham, R., Lerch, J., Ehrnhoefer, D., Cao, L.P., Zhang, W.N., Deng, Y., Bissada, N., Henkelman, R., et al. (2011) Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease. Mol. Neurodegener., 6, 59.
71. Smith, G.A., Rocha, E.M., McLean, J.R., Hayes, M.A., Izen, S.C., Isacson, O. and Hallett, P.J. (2014) Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease. Hum. Mol.Genet., 23, 4510-4527.
72. Indersmitten, T., Tran, C.H., Cepeda, C. and Levine, M.S. (2015) Altered excitatory and inhibitory inputs to striatal medium-sized spiny neurons and cortical pyramidal neurons in the Q175 mouse model of Huntington's disease. J. Neurophysiol., 113, 2953-2966.